Clinical Trial

Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

Study acronym: GUARD
Recruiting
View on ClinicalTrials.gov →
Summary
The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.
Protocol Amendment History 1 change
notable Trial sites expanded: 3 -> 10 locations 2026-04-09
Trial Details
NCT Number NCT06872684
Lead Sponsor Stryker Neurovascular
Conditions Aneurysm, Aneurysm, Intracranial
Enrollment 183 participants
Start Date 2025-06-20
Primary Completion 2029-01-31 (estimated)
Study Completion 2031-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-08